OncLive TV

James Ignatz-Hoover, MD, PhD, discusses the future of CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma.

David Rimm, MD, PhD, discusses challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current diagnostic kits.

Coral Olazagasti, MD discusses a tailored lung cancer screening program for Hispanic head and neck cancer survivors.

Jonathan C. Trent, MD, PhD discusses bezuclastinib plus sunitinib in gastrointestinal stromal tumors with imatinib resistance or intolerance.

Mikkael A. Sekeres, MD, discusses preliminary outcomes with oral azacitidine in lower-risk myelodysplastic syndromes, as reported in the ASTREON trial.

Stephen J. Freedland, MD, discusses the effects of treatment suspension on HRQOL in nonmetastatic hormone-sensitive prostate cancer in the EMBARK trial.

Marijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.

John Heymach, MD, PhD, discusses perioperative durvalumab in patients with resectable non-small cell lung cancer.

Joshua Linscott, MD, discusses using urinary cell-free tumor DNA to predict minimal residual disease in high-risk non-muscle invasive bladder cancer.

Christos Kyriakopoulos, MD discusses adding cabazitaxel to abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer.

Bertrand Arnulf, MD, PhD, discusses patient factors and pharmacodynamic biomarkers that impact survival outcomes with ide-cel in multiple myeloma.

Harry Erba, MD, PhD, discusses the safety profile of quizartinib according to treatment phase and age in newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Radhika Bansal, MBBS, discusses outpatient administration of axi-cel and brexu-cel in relapsed/refractory non-Hodgkin lymphoma.

David Samuel Dicapua Siegel, MD, discusses real-world outcomes with tandem transplantation in newly diagnosed multiple myeloma.

Axel Hauschild, MD, PhD, discusses the role of adjuvant and neoadjuvant therapy in melanoma, highlighting the utility of perioperative approaches.

Philip McCarthy, MD, discusses findings from an investigation, assessing the impact of neutrophils within the tumor microenvironment of multiple myeloma.

Lova L. Sun, MD, MSCE discusses tisotumab vedotin (in patients with recurrent or metastatic (r/m) head and neck squamous cell carcinoma.

Robert M. Rifkin, MD, FACP, discusses the use of prophylactic tocilizumab to reduce teclistamab-related CRS in relapsed/refractory myeloma.

Ahmad Tarhini, MD, PhD, discusses a prognostic model evaluating patients with advanced melanoma treated with immune checkpoint inhibitors.

Allison Winter, MD, discusses unmet needs for patients with Richter transformation from CLL.

Rocio Garcia-Carbonero, MD, discusses the rationale for the phase 2b VIRAGE trial in patients with metastatic pancreatic cancer.

Andrew Ip, MD, discusses alternative splicing of the TNFRSF17 gene, which encodes BCMA, in patients with lymphoma or multiple myeloma.

Anthony B. El-Khoueiry, MD, on data for regorafenib plus pembrolizumab in pretreated advanced hepatocellular carcinoma.

Daniel King, MD, PhD, discusses the need to develop less-toxic regimens for advanced gastrointestinal cancers.

Heinz-Josef Lenz, MD, FACP, discusses updated data for nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Emrullah Yilmaz, MD, PhD, discusses HB-200 arenavirus–based immunotherapy plus pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer.

Marc-Oliver Grimm, MD discusses darolutamide in combination with androgen deprivation therapy and docetaxel in mHSPC.

Eric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.

Catherine E. Lai, MD, MPH, discusses NCCN guideline updates regarding AML maintenance therapy, sharing how these updates influence treatment decisions.

David Braun, MD, PhD, discusses findings from the molecular analysis of the HCRN GU16-260-Cohort A study.